The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dissecting the immune infiltrate induced by ADT and PD-1 blockade in men with metastatic hormone-sensitive prostate cancer using single-cell RNA-sequencing.
 
Jessica Hawley
No Relationships to Disclose
 
Aleksandar Obradovic
No Relationships to Disclose
 
Xinzheng Victor Guo
No Relationships to Disclose
 
Matthew Chaimowitz
No Relationships to Disclose
 
Clara A Easterlin
No Relationships to Disclose
 
Matthew Dallos
No Relationships to Disclose
 
Emerson A. Lim
No Relationships to Disclose
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; Harpoon therapeutics; Kleo Pharmaceuticals; Tizona Therapeutics, Inc.; Urogen pharma; Werewolf Therapeutics
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Compugen; F-Star; Ferring; Genocea Biosciences; Janssen Oncology; Kleo Pharmaceuticals; Merck; Merck Serono; Pfizer; Pierre Fabre; Roche/Genentech; Shattuck Labs; Tizona Therapeutics, Inc.; Urogen pharma; Werewolf Therapeutics
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Merck Sharp & Dohme; Pfizer; Roche/Genentech
 
Mark N. Stein
Consulting or Advisory Role - Exelixis; Exelixis; Merck Sharp & Dohme
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)